Chemomab Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Chemomab's estimated annual revenue is currently $6.6M per year.(i)
  • Chemomab's estimated revenue per employee is $201,000

Employee Data

  • Chemomab has 33 Employees.(i)

Chemomab's People

NameTitleEmail/Phone
1
Consulting VP, Investor & Public Relations, Strategic CommunicationsReveal Email/Phone
2
VP, Global Clinical Development OperationsReveal Email/Phone
3
Associate Director, Preclinical DevelopmentReveal Email/Phone
4
Clinical Trial ManagerReveal Email/Phone
5
Project ManagerReveal Email/Phone
6
Senior Clinical Research AssociateReveal Email/Phone
7
Project LeaderReveal Email/Phone
8
Research AssistantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Chemomab?

Chemomab Ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases. Chemomab is making great strides with its novel CM-101 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. CM-101, the company's lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis and Non-alcoholic Steatohepatitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).

keywords:N/A

N/A

Total Funding

33

Number of Employees

$6.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Chemomab News

2022-04-13 - Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Expected to ...

Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases.

2022-03-22 - CHEMOMAB THERAPEUTICS LTD. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)

CHEMOMAB THERAPEUTICS LTD. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) ... and the related...

2022-03-22 - Chemomab Therapeutics Announces Fourth Quarter and Year ...

Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6M33-43%N/A
#2
$7.5M333%N/A
#3
$4.8M3332%N/A
#4
$4.2M336%N/A
#5
$6.7M330%N/A